Recursion Logo.jpg
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
08 août 2024 14h41 HE | Recursion Pharmaceuticals
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional...
Combo Pipeline
Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
08 août 2024 07h30 HE | Recursion Pharmaceuticals
Recursion entered into a definitive agreement to combine with Exscientia to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilitiesRecursion...
Recursion updates L(
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
08 août 2024 01h32 HE | Recursion Pharmaceuticals
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates...
Recursion to Report
Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th
05 août 2024 16h01 HE | Recursion Pharmaceuticals
Salt Lake City, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide...
Recursion Announces
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
26 juin 2024 22h07 HE | Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion Announces
Recursion Announces Proposed Offering of Class A Common Stock
26 juin 2024 16h06 HE | Recursion Pharmaceuticals
Salt Lake City, June 26, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug...
Recursion to Partici
Recursion to Participate in Upcoming Investor Conferences
03 juin 2024 09h00 HE | Recursion Pharmaceuticals
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its...
Power of Recursion O
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
29 mai 2024 15h27 HE | Recursion Pharmaceuticals
SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature...
Recursion Appoints R
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
24 mai 2024 16h30 HE | Recursion Pharmaceuticals
SALT LAKE CITY, May 24, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that Robert...
Recursion Announces
Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry
13 mai 2024 05h00 HE | Recursion Pharmaceuticals
SALT LAKE CITY, May 13, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the completion...